Printer Friendly

Neurocrine Biosciences Inc.

NEUROCRINE BIOSCIENCES INC. (San Diego CA) said an experimental depression drug it was developing with GlaxoSmithKline Plc (London GBR) failed in a mid-stage trial to work better than a placebo. Neurocrine said it plans to meet with Glaxo in the coming months to determine the next steps for the depression program. The Phase 2 trial, which involved 150 patients experiencing a major depressive episode, found no benefit for patients treated with the experimental drug, a corticotropin releasing factor (CRF1) receptor antagonist called GSK561679. Three separate academic collaborative clinical trials are ongoing to evaluate the effects of GSK561679 in post traumatic stress disorder, anxiety and alcoholism.

Shares of Neurocrine Biosciences closed the week up 4 cents at $5.74 on Nasdaq.
COPYRIGHT 2010 MedContent Media, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CORPORATE
Date:Sep 20, 2010
Previous Article:Geron Corp.
Next Article:Nupathe Inc.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters